Target Mast cells
| Zeile 18: | Zeile 18: | ||
'''Cromoglycate''' | '''Cromoglycate''' | ||
{{tp|p=32460208|t=2020. Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19.|pdf=|usr=009}} | {{tp|p=32460208|t=2020. Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19.|pdf=|usr=009}} | ||
| + | |||
| + | '''H1 antihistamines''' | ||
| + | '''Famotidine''' | ||
| + | {{tp|p=32579065|t=2020. Binding insight of clinically oriented drug famotidine with the identified potential target of SARS-CoV-2.|pdf=|usr=010}} | ||
Version vom 8. Juli 2020, 09:24 Uhr
'bradykinin antagonists Icatibant, Noscapine
| 32337769 2020. (tt bradykinin) Noscapine, a possible drug candidate for attenuation of cytokine release associated with SARS-CoV-2 |
32359101 2020. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications
32526773 2020. Impaired Breakdown of Bradykinin and Its Metabolites as a Possible Cause for Pulmonary Edema in COVID-19 Infection.
32359101 2020. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications
Apremilast
32449265 2020. Apremilast as a potential treatment option for COVID-19: no symptoms of infection in a psoriatic patient.
Montelukast
32492562 2020. The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast.
32416408 2020. As a potential treatment of COVID-19: Montelukast.
32586154 2020. Montelukast's ability to fight COVID-19 infection.
Cromoglycate
32460208 2020. Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19.
H1 antihistamines
Famotidine
32579065 2020. Binding insight of clinically oriented drug famotidine with the identified potential target of SARS-CoV-2.
